Dundee J W, Collier P S, Carlisle R J, Harper K W
Br J Clin Pharmacol. 1986 Apr;21(4):425-9. doi: 10.1111/j.1365-2125.1986.tb05217.x.
The pharmacokinetics of a fixed dose of midazolam (0.3 mg kg-1 i.v.) were studied in detail in 115 healthy patients or volunteers and nine were found with a prolonged elimination half-life. A further 102 patients had an abbreviated pharmacokinetic study, of whom five showed a similar abnormality. Defective hepatic metabolism of midazolam may be a factor in the aetiology of what appears to be a true phenomenon, occurring in 6% of over 200 fit subjects given a standard dose of the drug.
对115名健康患者或志愿者详细研究了固定剂量咪达唑仑（0.3mg/kg静脉注射）的药代动力学，发现9人消除半衰期延长。另外102名患者进行了简略的药代动力学研究，其中5人表现出类似异常。咪达唑仑肝脏代谢缺陷可能是在给予标准剂量该药的200多名健康受试者中6%出现的这一似乎真实存在的现象病因中的一个因素。
